Travoprost
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Travoprost: From Glaucoma / Ocular Hypertension to Visceral Calciphylaxis
One-Sentence Summary
Travoprost is a prostaglandin F2α receptor (FP receptor) agonist, originally used topically to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The TxGNN model’s top-ranked prediction suggests potential relevance to Visceral Calciphylaxis, but this signal is currently supported by 0 clinical trials and 0 publications, and the evidence pack itself flags it as lacking biological plausibility.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Open-Angle Glaucoma / Ocular Hypertension (IOP-lowering, topical) |
| Predicted New Indication | Visceral Calciphylaxis |
| TxGNN Prediction Score | 99.9998% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data for Travoprost is not available in this evidence pack. Based on known pharmacology, Travoprost is a prostaglandin F2α analogue acting as an FP-receptor agonist, primarily applied topically to reduce intraocular pressure by increasing uveoscleral outflow.
However, per the evidence pack’s own mechanistic assessment, no established pharmacological link exists between FP-receptor agonism and visceral calciphylaxis — a condition driven by vascular calcification leading to ischemic skin/organ necrosis. The repurposing rationale explicitly states this is “無已知機轉關聯…純屬 TxGNN 知識圖譜的統計預測，缺乏生物學合理性論述” (no known mechanistic association; a purely statistical prediction from the TxGNN knowledge graph, lacking biological plausibility).
This candidate should therefore be treated as a hypothesis-generating computational signal only, not a mechanistically supported repurposing candidate.
Note: A lower-ranked candidate in this evidence pack — “vascular disease” (rank 5) — has actual supporting clinical trials and literature (evidence level L3, decision stage S1, “Research Question”), reflecting travoprost’s known pharmacological effect on ocular/retinal vasculature (e.g., choroidal blood flow, conjunctival hyperemia). This may be a more tractable direction for further investigation than the top-ranked visceral calciphylaxis prediction.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
India Market Information
Travoprost currently has no market authorization in this jurisdiction (Not Marketed; 0 registrations on file).
Safety Considerations
- Drug Interactions: 49 potential interactions recorded (source: DDInter). The source database does not classify severity levels for these pairs (all listed as “Unknown”). Notable interacting agents include: Calcitriol, Pantoprazole, Sucralfate, Morphine, Metformin, Omeprazole, Rosiglitazone, Lansoprazole, Lactulose, Triamcinolone, Prednisone, Simvastatin, Potassium chloride, Prednisolone, Ranitidine, Ondansetron, Metronidazole, Famotidine, Acetylsalicylic acid, and Glyburide (20 of 49 total shown).
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (visceral calciphylaxis) carries an extremely high TxGNN score but has zero clinical trials, zero literature, and — per the evidence pack’s own rationale — no coherent mechanistic basis (L5, decision stage S0). This is a pure computational association without biological or clinical validation and does not meet the threshold to advance.
To proceed, the following is needed:
- TFDA/equivalent package insert warnings and contraindications (currently a blocking data gap, DG001)
- Confirmed mechanism of action documentation for Travoprost (DG002)
- A biologically grounded mechanistic hypothesis linking FP-receptor agonism to vascular calcification pathways, before any preclinical work is justified
- If pursuing a repurposing signal at all, consider prioritizing the “vascular disease” candidate (rank 5), which already has L3-level trial/literature support around travoprost’s ocular vascular effects
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.